Padmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock (2024)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 14,491 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $35.31, for a total transaction of $511,677.21. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $32.75 on Tuesday. The company's 50-day moving average price is $29.87 and its two-hundred day moving average price is $28.10. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $39.09.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). The company had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The firm's quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. Equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Did you make $29,000 two days with AI options trades?

From Prosper Trading Academy | Ad

What if it was possible to find options trades on autopilot…Using A.I. to find the ones with the highest profit potential…And nearly perfect win rates…You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:

Click Here To Get Your Free Copy

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. Loomis Sayles & Co. L P grew its stake in shares of Supernus Pharmaceuticals by 8.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company's stock worth $47,703,000 after purchasing an additional 136,964 shares during the last quarter. QRG Capital Management Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter worth approximately $416,000. Lazard Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 170.8% in the 3rd quarter. Lazard Asset Management LLC now owns 11,905 shares of the specialty pharmaceutical company's stock worth $327,000 after purchasing an additional 7,508 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,430,916 shares of the specialty pharmaceutical company's stock worth $73,073,000 after purchasing an additional 39,650 shares during the last quarter. Finally, Illinois Municipal Retirement Fund acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter worth approximately $858,000.

Supernus Pharmaceuticals Company Profile

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.